Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.34 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A known ✓ | Q03164 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 9/20 | 0.35 |
| ▸ | SLC16A3 | O15427 | 2/20 | 0.34 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.34 |
| ▸ | FPR1 | P21462 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL4131318 | 1.00 | NAMPT (0.35) | NAMPTSLC6A2SLC6A4SLC6A3SLC16A3 | |
| SCHEMBL3695531 | 0.93 | SLC6A4 (0.39) | NAMPTSLC6A2SLC6A4SLC6A3SLC16A3 | |
| Fumaric Acid SCHEMBL3704584 | 0.91 | NAMPT (0.36) | NAMPTSLC6A2SLC6A4SLC6A3SLC16A3 | |
| Fumaric Acid SCHEMBL3704583 | 0.91 | NAMPT (0.36) | NAMPTSLC6A2SLC6A4SLC6A3SLC16A3 | |
| Fumaric Acid SCHEMBL3706637 | 0.90 | SLC16A3 (0.32) | NAMPTSLC16A3SLC16A1FPR1 | |
| Fumaric Acid SCHEMBL4126776 | 0.90 | NAMPT (0.35) | NAMPTSMN1; SMN2ALDH1A1GAACYP2C9 | |
| Fumaric Acid SCHEMBL4126782 | 0.90 | NAMPT (0.35) | NAMPTSMN1; SMN2ALDH1A1GAACYP2C9 | |
| Fumaric Acid SCHEMBL4136246 | 0.89 | NAMPT (0.38) | NAMPTSLC16A3SLC16A1SMN1; SMN2MEN1 | |
| Fumaric Acid SCHEMBL4136237 | 0.89 | NAMPT (0.38) | NAMPTSLC16A3SLC16A1SMN1; SMN2MEN1 | |
| Fumaric Acid SCHEMBL3705828 | 0.89 | P2RX7 (0.36) | NAMPTSLC6A4SMN1; SMN2ALDH1A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | SLC6A2 3641/4885SLC6A4 3372/4885SLC6A3 4450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.